01:55 AM EDT, 09/18/2026 (MT Newswires) -- Sandoz Group (SDZ.SW) agreed with biopharmaceutical company mAbxience to develop a biosimilar version of Hemlibra, or emicizumab, a treatment for hemophilia A. The Swiss drugmaker said Friday it will have exclusive global commercialization rights for the proposed emicizumab biosimilar, excluding Argentina, Uruguay, and Paraguay, while mAbxience will handle development and manufacturing.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.